The authors have designated this AOP as all rights reserved. Re-use in any form requires advanced permission from the authors.

AOP: 553

Title

A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
Na⁺ channels, cardiomyopathy
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v2.7

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool

Authors

The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

Sun-Woong Kanga, Myeong Hwa Song,Do-Sun Lim b and Kim Young Jun

aCenter for Biomimetic Research, Korea Institute of Toxicology, Daejeon 34114, Korea

bCardiovascular Center, Department of Cardiology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea

cEnvironemental Safety Group, KIST Europe, campus E 71 Saarbruecken, Germany 

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help
Young Jun Kim   (email point of contact)

Contributors

Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Young Jun Kim

Coaches

This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
This AOP was last modified on December 03, 2024 09:31

Revision dates for related pages

Page Revision Date/Time
Inhibition, sodium channel September 16, 2017 10:15
Altered, Action Potential March 31, 2022 06:49
Decrease, Cardiac contractility June 19, 2018 14:02
Heart failure December 03, 2024 10:15
Inhibition, sodium channel leads to Altered, Action Potential November 21, 2024 09:58
Altered, Action Potential leads to Decrease, Cardiac contractility November 21, 2024 09:58
Decrease, Cardiac contractility leads to Heart failure January 05, 2023 07:48
Lidocaine November 29, 2016 18:42
Flecainide November 21, 2024 09:40
Bupivacaine November 21, 2024 09:40
Tetracaine November 21, 2024 09:40
Tetrodotoxin November 29, 2016 18:42
Saxitoxin November 21, 2024 09:41
Pyrethrins and Pyrethroids November 29, 2016 18:42
p,p'-DDT December 20, 2018 07:53
Tetrodotoxin derivatives November 21, 2024 09:42

Abstract

A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

Voltage-gated sodium channels (Na⁺ channels) are critical for initiating and propagating action potentials in cardiac myocytes. Their inhibition can trigger a cascade of biological events culminating in heart failure, which can be conceptualized within an Adverse Outcome Pathway (AOP) framework. The molecular initiating event (MIE) of Na⁺ channel inhibition reduces sodium ion influx, impairing the depolarization phase of cardiac action potentials. This leads to key events (KEs) such as reduced action potential amplitude, disrupted cardiac electrical conductance, decreased cardiac contractility, and compromised cardiac output. Prolonged dysfunction triggers maladaptive stress responses, including fibrosis, hypertrophy, and apoptosis, ultimately resulting in heart failure as the adverse outcome (AO). Key event relationships (KERs) provide mechanistic insights into this progression, linking reduced Na⁺ influx to impaired electrical and mechanical function through calcium dysregulation and myocardial remodeling. Developing this AOP requires robust empirical evidence, biological plausibility, and an understanding of modulating factors such as genetic predisposition and comorbidities. Quantitative modeling of the dose-response and temporal relationships between KEs and the AO will enhance predictive capability and inform risk assessment. This AOP framework offers a structured approach for studying the cardiotoxic effects of Na⁺ channel inhibitors, identifying potential biomarkers, and guiding therapeutic interventions to mitigate heart failure.

AOP Development Strategy

Context

Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

Inhibition of sodium channel conductance can contribute to the development of cardiomyopathy through its impact on cardiac electrophysiology, ion homeostasis, and mechanical function. Voltage-gated sodium channels, primarily Nav1.5 (encoded by SCN5A), are essential for rapid depolarization during the cardiac action potential. Inhibition of sodium channel conductance reduces the inward sodium current (INa), leading to slowed conduction velocity, conduction blocks, and increased susceptibility to arrhythmias. These electrical abnormalities impose hemodynamic stress on the myocardium, promoting maladaptive remodeling. Sodium channel inhibition also disrupts the sodium gradient, impairing the sodium-calcium exchanger (NCX) and causing calcium overload, oxidative stress, mitochondrial dysfunction, and myocyte apoptosis. Chronic electromechanical dysfunction can lead to ventricular dilation and the progression of dilated cardiomyopathy (DCM). Conditions associated with sodium channel inhibition include genetic mutations, such as SCN5A mutations in Brugada syndrome and Lenègre disease, drug-induced sodium channel blockade from Class I antiarrhythmics, and ischemia-induced sodium channel dysfunction. These pathologies manifest as arrhythmias, heart failure, and an increased risk of sudden cardiac death. Understanding the role of sodium channel inhibition in cardiomyopathy highlights the need for targeted interventions to prevent the progression of sodium channel-related cardiac dysfunction.

Strategy

Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

This AOP describes the sequence of biological events triggered by Na⁺ channel inhibition, beginning with the molecular initiating event (MIE) and culminating in cardiomyopathy as the adverse outcome (AO). Key events (KEs) include impaired action potential propagation, disrupted calcium homeostasis, reduced cardiac contractility, and maladaptive remodeling of cardiac tissue. These events are supported by empirical and mechanistic evidence, with temporal and dose-response concordance observed in experimental studies. This AOP provides a structured framework for assessing the cardiotoxicity of compounds targeting Na⁺ channels and identifying biomarkers and intervention points to mitigate the risk of cardiomyopathy.

1. Problem Formulation

Define the Scope and Purpose:

Clearly outline the biological context, regulatory application, and the specific chemical, biological, or environmental perturbation under investigation (e.g., Na⁺ channel inhibitors leading to heart failure).

Identify Stakeholders:

Engage stakeholders from academia, industry, and regulatory agencies to align the AOP objectives with practical needs, such as risk assessment or prioritization of chemical testing.

2. Identification of Key Events (KEs)

Molecular Initiating Event (MIE):

Pinpoint the initial perturbation at the molecular level (e.g., inhibition of Na⁺ channels). This is the starting point of the AOP.

Intermediate Biological Events:

Identify key biological responses at the cellular, tissue, organ, and organism levels. For example:

Reduced action potential amplitude.

Disrupted electrical conductance in cardiomyocytes.

Decreased cardiac contractility and output.

Adverse Outcome (AO):

Define the final negative impact on health, such as heart failure.

3. Establish Key Event Relationships (KERs)

Mechanistic Linkages:

Define how each KE leads to the next. For example:

Reduced Na⁺ influx → Reduced action potential amplitude.

Disrupted electrical signaling → Decreased cardiac output.

Empirical Evidence:

Gather and analyze data to support the strength, consistency, and specificity of the relationships between KEs.

Temporal and Dose-Response Concordance:

Ensure that the sequence and intensity of events align logically with biological plausibility and experimental data.

4. Data Gathering and Analysis

Literature Review:

Perform a systematic review to collate existing studies on the MIE, KEs, and AO.

Experimental Data:

Use in vitro, in vivo, or computational models to fill knowledge gaps, focusing on dose-response, time-course studies, and species-specific effects.

Data Integration Tools:

Leverage tools like AOP-Wiki for organizing data and mapping KEs and KERs.

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help

Events:

Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
MIE 584 Inhibition, sodium channel Inhibition, sodium channel
KE 698 Altered, Action Potential Altered, Action Potential
KE 1532 Decrease, Cardiac contractility Decrease, Cardiac contractility
AO 1535 Heart failure Heart failure

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help
Life stage Evidence
Not Otherwise Specified Moderate

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help
Term Scientific Term Evidence Link
human Homo sapiens High NCBI
rodents rodents High NCBI
dogs Canis lupus familiaris High NCBI
pigs Sus scrofa High NCBI
fish fish Moderate NCBI
insects insects Low NCBI

Sex Applicability

The sex for which the AOP is known to be applicable. More help
Sex Evidence
Mixed High

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

1. Molecular Initiating Event (MIE)

Inhibition of Voltage-Gated Sodium Channels (Na⁺ Channels): Reduced Na⁺ influx due to channel inhibition disrupts the depolarization phase of the cardiac action potential, impairing electrical activity in cardiomyocytes.

2. Key Events (KEs)

KE1: Reduced Action Potential Propagation

Decreased Na⁺ influx reduces the amplitude and speed of action potential propagation in cardiac cells. This leads to electrical conduction delays, arrhythmias, and asynchronous contraction of the myocardium.

Voltage-gated Na⁺ channel dysfunction affects downstream ion exchange mechanisms, particularly the Na⁺/Ca²⁺ exchanger. This disrupts intracellular calcium levels, which are essential for excitation-contraction coupling.

KE2: Decreased Cardiac Contractility

Impaired calcium handling reduces myocyte contractile force. This weakens overall cardiac output and increases stress on the myocardium.

3. Adverse Outcome (AO)

Cardiomyopathy:

Chronic mechanical and oxidative stress from reduced contractility initiates maladaptive remodeling, including:

Fibrosis: Excessive deposition of extracellular matrix proteins.

Hypertrophy: Enlargement of cardiomyocytes.

Apoptosis: Programmed cell death of cardiac cells.

A progressive disorder characterized by structural abnormalities (e.g., fibrosis, hypertrophy) and functional impairments (e.g., reduced ejection fraction), ultimately compromising cardiac performance and increasing the risk of heart failure.

4. Key Event Relationships (KERs)

KER1: Na⁺ Channel Inhibition → Reduced Action Potential Propagation

Strong mechanistic evidence supports the role of Na⁺ channels in driving the depolarization phase of action potentials. Their inhibition disrupts electrical signaling in cardiomyocytes.

KER2: Reduced Action Potential Propagation → Decreased Cardiac Contractility

Altered electrical activity impacts calcium cycling, particularly through voltage-gated calcium channels and Na⁺/Ca²⁺ exchangers, leading to imbalanced intracellular calcium.

Calcium is a critical regulator of cardiomyocyte contraction. Disrupted calcium homeostasis diminishes excitation-contraction coupling, leading to weaker contractions.

KER3: Decreased Cardiac Contractility → Cardiomyopathy

Fibrosis, hypertrophy, and cell death reduce myocardial efficiency and elasticity, resulting in the structural and functional impairments characteristic of cardiomyopathy.

5. Biological Plausibility

The role of Na⁺ channels in cardiac electrophysiology and their influence on calcium cycling is well-established.

Chronic impairments in contractility and stress response are known drivers of maladaptive remodeling and cardiomyopathy.

6. Empirical Evidence

Temporal Concordance: Studies show a stepwise progression from Na⁺ channel inhibition to structural and functional myocardial changes.

Dose-Response Relationship: Increasing levels of Na⁺ channel inhibitors correlate with more severe effects on electrical and mechanical function.

Species Relevance: Evidence exists across multiple species, including humans, rodents, and non-human primates.

7. Modulating Factors

Intrinsic Factors: Genetic mutations in Na⁺ channel genes (e.g., SCN5A) can exacerbate susceptibility.

Extrinsic Factors: Co-exposure to other cardiotoxic agents, ischemia, or oxidative stress may influence pathway progression.

8. Regulatory and Practical Utility

Chemical Risk Assessment: This AOP can help identify and prioritize chemicals with potential cardiotoxic effects for further testing.

Biomarker Development: Intermediate KEs, such as impaired calcium homeostasis, can serve as early indicators of cardiomyopathy.

Alternative Testing Methods: The AOP provides a framework for in vitro and computational models to evaluate cardiotoxicity without relying on animal testing.

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help
  • High Relevance Across Vertebrates:
    • Voltage-gated Na⁺ channels are evolutionarily conserved across vertebrate species, including humans, rodents, and non-human primates.
    • Cardiomyopathy-related structural and functional responses, such as fibrosis and hypertrophy, are also conserved, supporting broad taxonomic applicability.
  • Empirical Evidence:
    • Studies in humans and animal models (e.g., mice, rats, dogs) demonstrate similar pathological responses to Na⁺ channel inhibition.
    • Specific Na⁺ channel subtypes (e.g., SCN5A) are well-characterized in these species, with functional roles and perturbations largely consistent.

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

Key Events (KEs) and Their Essentiality

1. Molecular Initiating Event (MIE): Inhibition of Voltage-Gated Sodium Channels (Na⁺ Channels)

Essentiality: High

Voltage-gated sodium channels are fundamental to cardiac electrophysiology. Their inhibition initiates the cascade of downstream effects.

Experimental evidence: Pharmacological or genetic inhibition of Na⁺ channels results in immediate effects on action potential generation and propagation in cardiomyocytes.

2. KE1: Reduced Action Potential Propagation

Essentiality: High

Sodium channels drive the depolarization phase of cardiac action potentials, which is crucial for electrical signal propagation.

Perturbation of action potential propagation disrupts the coordinated contraction of the heart.

Supporting evidence: Experimental blockade of Na⁺ channels leads to reduced action potential amplitude and conduction velocity in vitro and in vivo.

3. KE2: Decreased Cardiac Contractility

Essentiality: High

Reduced contractility directly impacts cardiac output and places mechanical stress on the myocardium, driving compensatory and maladaptive responses.

This KE represents a critical tipping point for the transition from functional impairment to pathological remodeling.

Supporting evidence: Cardiac-specific suppression of contractility in animal models induces myocardial remodeling and dysfunction.

Adverse Outcome (AO): Cardiomyopathy

Essentiality: Outcome

Cardiomyopathy represents the ultimate pathological state resulting from the preceding key events.

Fibrosis, hypertrophy, and apoptosis are central to the structural changes observed in cardiomyopathy. However, the extent of remodeling may vary depending on compensatory mechanisms and external factors.

Supporting evidence: Chronic stress on the myocardium (e.g., due to reduced contractility or electrical dysfunction) induces remodeling in experimental models. Reversing the stress (e.g., unloading the heart) reduces remodeling severity.

Supporting Evidence for Essentiality

Chemical Inhibition Studies:

Selective inhibitors of Na⁺ channels produce predictable downstream effects, from electrical dysfunction to structural remodeling and cardiomyopathy.

Genetic Models:

Knockout or knockdown of Na⁺ channel genes (e.g., SCN5A) in animal models recapitulates the AOP, demonstrating the essentiality of upstream events.

Rescue Studies:

Interventions targeting specific KEs (e.g., restoring calcium homeostasis or contractility) prevent or reverse downstream events, confirming the necessity of the targeted KE.

Temporal Concordance:

The progression of events aligns temporally, with perturbation of upstream KEs preceding and enabling downstream effects.

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help
  • Empirical Evidence:
    • Na⁺ channel blockers (e.g., tetrodotoxin, lidocaine) reduce action potential amplitude and conduction velocity in cardiomyocytes in vitro and in vivo.
    • Temporal and dose-response concordance is well-documented.
    • Calcium dysregulation observed in experiments using Na⁺ channel inhibitors.
    • Perturbations in calcium transients measured in isolated cardiomyocytes following Na⁺ channel blockade.
    • Reduction in contractility observed in animal models treated with Na⁺ channel inhibitors.
    • Evidence from chronic studies shows structural changes (e.g., increased collagen deposition) in response to Na⁺ channel inhibitors.
    • Observations of hypertrophy and fibrosis in genetic models of Na⁺ channel dysfunction.
    • Dose-dependent reduction in action potential amplitude with Na⁺ channel inhibitors.

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help
Modulating Factor (MF) Influence or Outcome KER(s) involved

co-exposure to ion channel modulators

NCX functionality, electrolyte imbalances, cardiac load

Collagen turnover, chronic stress, anti-fibrotic therapies

Variations in the expression of auxiliary ion channels

(e.g., potassium or calcium channels) may buffer or enhance the effects of Na⁺ channel inhibition.

Increased or decreased conduction delays

Altered calcium cycling efficiency or partially mitigate contractility.

Increased fibrosis, hypertrophy, or apoptosis

KER1

KER2

KER3

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

MIE: Na⁺ Channel Inhibition

Quantitative Data:

IC50 values for Na⁺ channel blockers (e.g., tetrodotoxin, lidocaine) are well-established, indicating concentrations required for 50% inhibition of Na⁺ channels.

Example: Lidocaine IC50 for Nav1.5 channels in cardiomyocytes ~40 µM.

Key Metrics:

Degree of channel inhibition (e.g., 25%, 50%, 75%) correlates with the reduction in action potential amplitude.

KE1: Reduced Action Potential Propagation

Quantitative Data:

Direct measurements of action potential amplitude and conduction velocity under Na⁺ channel inhibition:

Reduced amplitude (~30-70%) with increasing inhibitor concentrations.

Slower conduction velocity in isolated cardiomyocytes and cardiac tissue slices.

Temporal Concordance:

Immediate effects observed within milliseconds to seconds after Na⁺ channel blockade.

Predictive Models:

Hodgkin-Huxley-type models simulate the effects of Na⁺ channel inhibition on action potential propagation.

KE2: Decreased Cardiac Contractility

Quantitative Data:

Fractional shortening and ejection fraction reductions correlate with impaired calcium handling:

20-50% reduction in intracellular calcium leads to a proportional decrease in contraction force.

Dose-dependent reductions in contractility observed in vitro and in vivo with Na⁺ channel blockers.

Na⁺/Ca²⁺ exchanger (NCX) activity reduction as a function of intracellular Na⁺ accumulation:

Example: 50% reduction in NCX flux correlates with ~30% decrease in calcium transients.

Measured changes in intracellular calcium levels (amplitude and duration of calcium transients).

Temporal Concordance:

Decreased contractility occurs within minutes to hours of calcium dysregulation.

Predictive Models:

Hill-type models describe the relationship between intracellular calcium levels and contraction force.

AO: Cardiomyopathy

Quantitative Data:

Myocardial stiffness increases by ~50-100% with fibrosis.

Left ventricular ejection fraction (LVEF) reduction by ~10-20% indicates significant dysfunction.

Chronic reductions in contractility and increased wall stress drive fibrosis and hypertrophy:

Fibrosis increases collagen content by ~30-50% after weeks of stress.

Hypertrophy measured as a ~20-40% increase in cardiomyocyte cross-sectional area.

Thresholds for stress-induced remodeling vary but are typically dose- and time-dependent.

Temporal Concordance:

Myocardial dysfunction occurs over weeks to months, following sustained remodeling.

Predictive Models:

Cardiac output and pressure-volume loop models predict functional impairments based on structural and mechanical changes.

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help

The Adverse Outcome Pathway (AOP) describing the inhibition of voltage-gated sodium channels (Na⁺ channels) leading to cardiomyopathy provides a structured framework for understanding the mechanistic progression from a molecular initiating event (MIE) to an adverse outcome (AO). Inhibition of Na⁺ channels disrupts action potential propagation, impairs calcium homeostasis, decreases cardiac contractility, triggers maladaptive cardiac remodeling, and ultimately results in myocardial dysfunction and cardiomyopathy. This pathway is supported by strong biological plausibility, empirical evidence, and emerging quantitative models that describe dose-response relationships and temporal concordance between key events (KEs).

The AOP has significant applications in chemical risk assessment, enabling screening and prioritization of chemicals, regulatory decision-making, and weight-of-evidence evaluations. In drug development, the AOP can guide preclinical safety testing, biomarker identification, and rational drug design to minimize cardiotoxicity. Additionally, it supports the development of alternative testing strategies, including in vitro and computational models, promoting the 3Rs (replacement, reduction, refinement) in toxicology. Environmental and ecological risk assessments can also benefit from this AOP, given the conserved role of Na⁺ channels across vertebrates.

Quantitative understanding of the AOP is advancing, with predictive models emerging for early KEs, such as reduced action potential propagation and impaired calcium cycling, though further work is needed for chronic effects like cardiac remodeling. Modulating factors, including genetic predispositions, comorbidities, and co-exposures, influence the progression and severity of the pathway, emphasizing the need for context-specific risk assessment tools.

This AOP provides a versatile framework for regulatory, scientific, and industrial applications. It supports the integration of mechanistic evidence into risk prediction, fosters the development of alternative testing methods, and facilitates cross-sector collaboration. By addressing current knowledge gaps and refining quantitative models, this AOP has the potential to significantly advance cardiotoxicity assessment and risk mitigation strategies for Na⁺ channel inhibitors and related compound

References

List of the literature that was cited for this AOP. More help

Archer, C. R., & Robinson, P. (2020). "Voltage-gated sodium channel inhibition and its effects on cardiac function." Journal of Cardiovascular Research, 89(5), 345–356.

Catterall, W. A. (2017). "Structure and Function of Voltage-Gated Sodium Channels." Annual Review of Biochemistry, 86, 569–590.

George, A. L., Jr. (2005). "Inherited disorders of voltage-gated sodium channels." Journal of Clinical Investigation, 115(8), 1990–1999.

Musa, H., et al. (2019). "The role of Na⁺ channel regulation in cardiomyopathy and arrhythmogenesis." Heart Rhythm, 16(9), 1344–1352.

Veerman, C. C., et al. (2015). "The role of sodium current in cardiac electrophysiology and arrhythmogenesis in human models." Frontiers in Physiology, 6, 1–15.

Yang, L., et al. (2018). "Voltage-gated sodium channels as therapeutic targets in cardiac diseases." Trends in Pharmacological Sciences, 39(6), 482–494.

Koenig, X., & Rubi, L. (2021). "Adverse cardiac effects of Na⁺ channel inhibitors: From action potential propagation to cardiomyopathy." Toxicology Letters, 345, 15–25.

Remme, C. A., & Wilde, A. A. M. (2014). "Inherited sodium channelopathies: A decade of progress." Journal of Clinical Investigation, 124(4), 2260–2267.

Veerman, C. C., Wilde, A. A. M., & Lodder, E. M. (2015). "The cardiac sodium channel gene SCN5A and its gene product Naᵥ1.5: Role in physiology and pathophysiology." Gene, 573(2), 177–187.

Powers, J. M., & Olson, T. M. (2020). "Genetics of dilated cardiomyopathy: The next generation." Circulation: Cardiovascular Genetics, 13(1), e002720.

Wang, D. W., & George, A. L. Jr. (2018). "Cardiac sodium channel mutations associated with dilated cardiomyopathy and arrhythmia." Electrophoresis, 39(12), 1535–1541.

Shy, D., Gillet, L., & Abriel, H. (2013). "Cardiac sodium channel Naᵥ1.5 distribution in myocytes via interacting proteins: The multiple pool model." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1833(4), 886–894.

Rook, M. B., et al. (2012). "Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with dilated cardiomyopathy." Circulation Research, 110(5), 674–682.

Makiyama, T., et al. (2008). "A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation." Journal of the American College of Cardiology, 52(16), 1326–1334.